Literature DB >> 16867897

Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Miwako Honda1, Shinichi Oka.   

Abstract

Antiretroviral treatments with highly active antiretroviral therapy (HAART) have shown remarkable progress in the past decade and resulted in impressive improvements in life expectancy and quality of life for patients infected with human immunodeficiency virus 1 (HIV-1). Despite the clinical benefits, the management of HIV infection faces many problems. Although HAART is able to suppress the viral load in the plasma, it is unable to eradicate it, and once HAART is initiated, treatment needs to be continued over a lifetime. The side effects of long-term HAART, such as lipodystrophy, lactic acidosis, insulin resistance, and hyperlipidemia, are negative impacts for patients who receive HAART. In addition, patients need to demonstrate high adherence to the therapy to achieve viral suppression and prevent the development of a drug-resistant virus. This review discusses currently recommended antiretroviral treatment strategies, the difficulties with antiretroviral treatments, and current issues regarding HIV management.

Entities:  

Mesh:

Year:  2006        PMID: 16867897     DOI: 10.1532/IJH97.06102

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  26 in total

1.  Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Joel E Gallant; Jean Anderson; James M Oleske; Howard Libman; Judith S Currier; Valerie E Stone; Jonathan E Kaplan
Journal:  Clin Infect Dis       Date:  2004-08-11       Impact factor: 9.079

Review 2.  Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

Authors:  Steven Grinspoon; Andrew Carr
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

3.  Decline in deaths from AIDS due to new antiretrovirals.

Authors:  R S Hogg; M V O'Shaughnessy; N Gataric; B Yip; K Craib; M T Schechter; J S Montaner
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

4.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Authors:  A N Phillips; S Staszewski; R Weber; O Kirk; P Francioli; V Miller; P Vernazza; J D Lundgren; B Ledergerber
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

5.  Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.

Authors:  O Gallego; C de Mendoza; M J Pérez-Elías; J M Guardiola; J Pedreira; D Dalmau; J Gónzalez; A Moreno; J R Arribas; A Rubio; I García-Arata; M Leal; P Domingo; V Soriano
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

6.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

7.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.

Authors:  John Christopher Walsh; Anton Louis Pozniak; Mark Richard Nelson; Sundhiya Mandalia; Brian George Gazzard
Journal:  J Acquir Immune Defic Syndr       Date:  2002-07-01       Impact factor: 3.731

9.  Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.

Authors:  Megan E O'Brien; Rebecca A Clark; C Lynn Besch; Leann Myers; Patricia Kissinger
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

10.  Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

Authors:  Felipe García; Elisa de Lazzari; Montserrat Plana; Pedro Castro; Gabriel Mestre; Meritxell Nomdedeu; Emilio Fumero; Esteban Martínez; Josep Mallolas; José L Blanco; José M Miró; Tomás Pumarola; Teresa Gallart; José M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-06-01       Impact factor: 3.731

View more
  3 in total

1.  MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

Authors:  Mark Eilers; Upal Roy; Debasis Mondal
Journal:  Exp Biol Med (Maywood)       Date:  2008-06-05

2.  Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.

Authors:  Kevin R Robillard; Gary N Y Chan; Guijin Zhang; Charles la Porte; William Cameron; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

3.  Lopinavir inhibits insulin signaling by promoting protein tyrosine phosphatase 1B expression.

Authors:  Takatoshi Kitazawa; Yusuke Yoshino; Satoshi Suzuki; Ichiro Koga; Yasuo Ota
Journal:  Exp Ther Med       Date:  2014-07-04       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.